TITLE

Prolidase Could Act as a Diagnosis and Treatment Mediator in Lung Fibrosis

AUTHOR(S)
Türkbeyler, Ibrahim; Demir, Tuncer; Pehlivan, Yavuz; Kaplan, Davut; Ceribasi, Ali; Orkmez, Mustafa; Aksoy, Nurten; Taysi, Seyithan; Kisacik, Bunyamin; Onat, Ahmet
PUB. DATE
October 2012
SOURCE
Inflammation;Oct2012, Vol. 35 Issue 5, p1747
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with unknown etiology and pathogenesis. With high mortality risks, most of the IPF cases emerged after a damage of alveolar epithelium, where this situation stimulates the over expression of matrix components. Inflammatory process observed as a reaction to emerged damage. Prolidase as an iminodipeptidase significantly increased during the development of fibrosis. The aim of this study is to measure prolidase activity as a marker of treatment and diagnosis in an experimental lung fibrosis animal model. Thirty male Wistar rats randomly divided into three experimental groups, with ten rats in each group. Group 1, control group; group 2, bleomycin (BLM)-induced lung fibrosis group, and group 3, BLM-induced lung fibrosis treated with palosuran (urotensin-II receptor antagonist). For histopathology, the middle lobes of right lungs were embedded in paraffin, followed by fixation in 10 % buffered formalin, and evaluation of IPF was performed using the Ashcroft scoring method. Prolidase activity was determined by a photometric method based on the measurement of proline levels produced by prolidase. The fibrosis scores and the prolidase activity were significantly enhanced by BLM stimulation. The BLM + palosuran treatment decreased prolidase activity in group 3. There was a positive correlation between prolidase activity and fibrosis scores. Palosuran seems to be effective in the treatment of lung fibrosis, and prolidase activity can be used for the diagnosis and/or for management of the treatment. However, further clinical and experimental studies with animals and/or patients are needed to verify these conclusions.
ACCESSION #
79861643

 

Related Articles

  • Approaches in Diagnosis and Treatment of Patients with Idiopathic Pulmonary Fibrosis: A Questionnaire Study. Anar, Ceyda; Okutan, Oğuzhan; Uzun, Oğuz; Özsu, Savaş; Altınsoy, Bülent // Eurasian Journal of Pulmonology;Aug2015, Vol. 17 Issue 2, p85 

    Objective: As Turkish Respiratory Society Diffuse Parenchymal Lung Diseases-Pulmonary Vascular Diseases Study Group (TRS DPLD-PVD SG), we aimed to demonstrate the approaches of physicians with a questionnaire toward the patients with IPF in our country. Methods: An invitation letter including a...

  • Updated International Guidelines for IPF.  // AARC Times;Oct2015, Vol. 39 Issue 10, p66 

    The article informs that the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Association have published updated guidelines on treating idiopathic pulmonary fibrosis (IPF).

  • The Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Behr, Jürgen // Deutsches Aerzteblatt International;12/23/2013, Vol. 110 Issue 51/52, following p875 

    Background: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial disease of the lung and has the worst prognosis of all such diseases, with a median survival time of three to four years. Its prevalence is 2-29 per 100 000 persons and its incidence approximately 10 per...

  • Interstitial lung disease: time to rethink the snapshot diagnosis? Antin-Ozerkis, Danielle; Kolb, Martin // Thorax;Jan2016, Vol. 71 Issue 1, p5 

    The article focuses on the need for diagnosis of idiopathic pulmonary fibrosis (IPF) to provide management decisions for its treatment. Topics discussed include a clinical-radiological-pathological multidisciplinary diagnosis implemented by the guidelines of the American Thoracic Society (ATS)...

  • How we will diagnose IPF in the future. Richeldi, L. // QJM: An International Journal of Medicine;2016 Supplement, Vol. 109, p581 

    The recent approval of two safe and effective treatments for patients with idiopathic pulmonary fibrosis (IPF) had as a direct consequence the absolute need for an accurate and early diagnosis. The standard approach to IPF diagnosis has proven to be effective and emphasized the importance of...

  • Precision medicine in idiopathic pulmonary fibrosis. Maher, T. M. // QJM: An International Journal of Medicine;2016 Supplement, Vol. 109, p585 

    No abstract available.

  • Novel approaches to pulmonary fibrosis. Jenkins, Gisli; Goodwin, Amanda // Clinical Medicine;2014 Supplement, Vol. 14, ps45 

    Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a poor prognosis and few treatment options. However, recent research into this condition has led to considerable insights into the pathophysiology of the disease, resulting in the identification of potential biomarkers to aid...

  • Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials? Jo Corte, Tamera; Goh, Nicole S.; Glaspole, Ian N.; Zappala, Christopher J.; Hopkins, Peter M.; Wilsher, Margaret L. // Thorax;May2013, Vol. 68 Issue 5, p491 

    A letter to the editor is presented in response to the article "Hot of the breath: mortality as a primary end-point in idiopathic pulmonary fibrosis (IPF) treatment trials: the best is the enemy of the good" by A.U. Wells and colleagues in the 2012 issue.

  • Increased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis. Buendía-Roldán, Ivette; Ruiz, Víctor; Sierra, Patricia; Montes, Eduardo; Ramírez, Remedios; Vega, Anita; Salgado, Alfonso; Vargas, Mario H.; Mejía, Mayra; Pardo, Annie; Selman, Moisés // PLoS ONE;12/15/2016, Vol. 11 Issue 12, p1 

    Idiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown etiology. The pathogenic mechanisms are unclear, but evidence indicates that aberrantly activated alveolar epithelial cells secrete a variety of mediators which induce the migration, proliferation and activation of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics